CLOUD COMPUTING – Using Quantum Molecular Design & Cloud Computing to Improve the Accuracy & Success Probability of Drug Discovery
Ed Addison and Shahar Keinan, PhD, explain how cloud computing combined with the continued influence of Moore’s Law has provided an unprecedented opportunity to apply inexpensive high-performance computing to drug discovery.
SPECIAL FEATURE – Advancements in Drug Delivery Technologies Tackle Solubility & Bioavailability Challenges
Contributor Cindy H. Dubin speaks with several innovator companies to learn more about the latest advances in drug delivery to address the challenging issues of solubility and bioavailability today
Andrew Birnie, PhD, explores how innovations in instruments, such as the Eco 48 real-time qPCR system (PCRmax), deliver exceptional uniformity, actively improving the reliability and productivity of the working laboratory.
David G. Watumull, President and CEO of Cardax, Inc, discusses the company’s plans to create a new platform for products in the consumer health and pharmaceutical markets based on the delivery of nature-identical astaxanthin.
IMMUNOASSAY PLATFORM – Accelerating Drug Development & Clinical Validation With Single Molecule Counting
Steven Suchyta, PhD, discusses how Ultrasensitive Single Molecule Counting technology provides an indispensable tool in the researcher’s arsenal to help move novel biology forward, fueling the discovery and development of new therapeutics.
NANOSCALE COMPLEXES – A Novel Nanotechnology-Based Platform to Optimize Combination Cancer Therapies: Rational Development & Improved Delivery Using CombiPlex®
Barry D. Liboiron, PhD; Arthur C. Louie, MD; et al describe how CombiPlex addresses the challenges facing the traditional development path of many contemporary drug combinations and provide clinical proof-of-principle evidence that this approach can yield marked improvements in efficacy and patient outcomes.
Bruno Speder and Adrian Wildfire, MS, describe how the concept is being applied to help develop vaccines against a number of common diseases, including influenza, rhinoviruses, respiratory syncytial virus, cholera, malaria, dengue, and Salmonella typhi.
EXECUTIVE INTERVIEW – Capsugel: Choosing the Right Pharmaceutical Design, Development & Manufacturing Partner
Pharmaceutical companies today increasingly require specialized design, development, and manufacturing partners to help bring new and improved drugs to market. These companies need partners of…
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.
COLORECTAL CANCER MARKET – Targeted & Immune System-Based Therapeutics Emerge as Prominent Treatment Modalities
Barbara Gilmore, Frost & Sullivan Analyst, reports that a vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and significant commercial potential are attracting drug developers to the market.
EXCLUSIVE ONLINE CONTENT
Translate Bio recently announced the closing of a previously announced research collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to…
WuXi Biologics and Immune Pharmaceuticals recently announced a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed…
Aclaris Therapeutics, Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aclaris’ investigational topical Janus Kinase (JAK) 1/3…
Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination With FluMist Influenza Vaccine
Hemispherx Biopharma, Inc. recently announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen in combination with FluMist…
Aurin Biotech’s ATAC, a drug which has successfully halted the growth of cancerous tumors, was recently awarded a patent (10,004,707 B2) by the United States…